Form 4: Monopar Therapeutics CFO Acquires Shares

Monopar Therapeutics Chief Financial Officer, Quan Anh Vu, has acquired shares through the vesting and settlement of restricted stock units, with a portion withheld for taxes.

Summary

• Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics, acquired 1,228 shares of common stock on June 30, 2026, through the vesting and settlement of restricted stock units (RSUs).
• Additionally, 507 shares were withheld by the issuer to cover applicable taxes due upon the vesting of these RSUs.
• Following these transactions, Mr. Vu beneficially owns 2,221 shares of common stock directly.
• The RSUs were originally granted on December 2, 2025, with a vesting schedule of 1,228 shares on June 30, 2026, and subsequent tranches every three months until full vesting on December 31, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation event for executive stock awards rather than a new investment or divestment decision.

Positives

• The Chief Financial Officer has acquired additional shares, indicating continued commitment to the company.
• The vesting of RSUs suggests that performance or service conditions tied to these awards have been met.
• The company is managing tax obligations related to RSU vesting by withholding shares.

Negatives

• A portion of the vested shares (507) were withheld by the company to cover taxes, reducing the immediate net share acquisition for the reporting person.

Risks

• The value of future RSU vesting is subject to the market price of Monopar Therapeutics' common stock.
• Potential for future share withholding for tax purposes could impact the net number of shares received by management.

Future Outlook

The vesting schedule for the remaining restricted stock units indicates future share issuances to Quan Anh Vu over the next several years, contingent upon continued service and the company's stock performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of shares by a CFO through RSU vesting, are common in the biotechnology and pharmaceutical sectors as a form of executive compensation and alignment with shareholder interests. The details of the vesting schedule and tax withholding are standard practice.

Stakeholder Impact

• Shareholders: The acquisition of shares by the CFO, even through RSU vesting, can be seen as a positive signal of management's long-term commitment.
• Employees: The RSU plan highlights a compensation strategy that aligns executive interests with company performance.
• Management: The CFO directly benefits from the company's stock performance through the vesting of RSUs.

Next Steps

• Continued vesting of restricted stock units for Quan Anh Vu according to the schedule through December 31, 2029.
• Potential future share withholding for tax purposes upon subsequent vesting events.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Share Acquisition, Quan Anh Vu, Chief Financial Officer, SEC Filing